20 results
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 May 24
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:15am
as of March 31, 2024, will enable it to fund its operating plan into 2026.
R&D Expense: Research and development expenses for the first quarter of 2024 were
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
external R&D at Eli Lilly, a public pharmaceutical company, from 2013 to 2014. Dr. Pinto holds a B.S. in Business Administration and Biochemistry from … Partners, a consulting company, from 2015 to 2016. Ms. Suh began her career in R&D strategy with the Regenerative Medicine group of GlaxoSmithKline
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023
7:08am
2023, Neumora announced that Robert Lenz, M.D., Ph.D., had joined Neumora as executive vice president, head of R&D. Dr. Lenz brings more than two … operating plan into 2026.
R&D Expense: Research and development expenses for the fourth quarter of 2023 were $38.9 million, as compared to $23.5 million
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
1 Nov 23
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:01pm
: In October 2023, Neumora announced that Robert Lenz, M.D., Ph.D., had joined Neumora as executive vice president, head of R&D. Dr. Lenz brings more than two
424B4
me2ixde xij8106hzvm
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
py22e
11 Sep 23
IPO registration (amended)
6:07am
S-1
oxyfs8hhp6cwr6w4q9
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.18
phibj8bmlax
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.5
hstt 5beswn
25 Aug 23
IPO registration
5:03pm
DRS/A
vm7k5
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.19
w5r0pqbmc8bw ei
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
mt5f 3r8s
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
ltvpsl7pil87m7
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
1dzslx
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
1dmvlkg ojq7gf
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
40pqyi0 ala
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
gnhqz8818 j3j
23 Dec 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.5
g7l6c4d5r33 btir
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
ylkvt6morfd1x6
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next